跳至主要内容
临床试验/NCT01682421
NCT01682421撤回不适用

Investigation of Treatment With Topical Corticosteroid After Posterior Lamellar Corneal Transplantation

Aarhus University Hospital1 个研究点 分布在 1 个国家开始时间: 2012年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
撤回
发起方
试验地点
1
主要终点
Freedom from rejection

研究概览

简要总结

After corneal transplantation, topical corticosteroids are used to reduce the risk of rejection.

However, the optimal postoperative treatment regimen is unknown. In most cases, a topical steroid is administered for at least 6 months after surgery, but it remains to be determined whether potent steroids offer better protection than weak steroids. Also, the length of the treatment is debated.

Since the use of steroids is not without potential serious ocular side effects, it is of considerable importance to investigate these problems.

The study aims to examine the frequency of rejection episodes after posterior lamellar keratoplasty; specifically comparing a short course of potent steroids versus a long course of weak steroids.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients treated for primary or secondary corneal endothelial failure at the department of ophthalmology, Aarhus University Hospital

排除标准

  • Not fulfilling the above

研究组 & 干预措施

Weak steroid

Experimental

Initial treatment with dexamethasone 6x per day for two weeks, followed by Fluorometholone 4x per day for 2 months, 3x per day for 2 months, 2x per day for 2 months, and finally 1x per day continually during 2 years.

干预措施: Weak steroid (Flurolon, Allergan) (Drug)

Potent steroid

Experimental

Initially Dexamethasone 6x per day for 2 weeks followed by 4x per day for one month, 3x per day for one month, 2x per day for one month, and finally 1x per day for one month - giving a total of 4,5 months of steroid treatment.

干预措施: Potent steroid (Maxidex, Alcon) (Drug)

结局指标

主要结局

Freedom from rejection

时间窗: 2 years

次要结局

未报告次要终点

研究者

发起方
Aarhus University Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Anders Ivarsen

MD, PhD

Aarhus University Hospital

研究点 (1)

Loading locations...

相似试验